title: Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.
abstract: Between 1998 and 2009, Bordetella pertussis clinical isolates were collected during three periods, i.e., 1998 to 2001 (n = 102), 2004 to 2005 (n = 154), and 2007 to 2009 (n = 140), from nine countries with distinct vaccination programs, i.e., Denmark, Finland, France, Germany, The Netherlands, Norway, Poland, Sweden, and the United Kingdom. Pulsed-field gel electrophoresis (PFGE) analysis was performed according to standardized recommendations for epidemiological typing of B. pertussis. There were 81 different PFGE profiles, five of which (BpSR3, BpSR5, BpSR10, BpSR11, and BpSR12) were observed in 61% of the 396 isolates and shown to be predominant in almost all countries. The major profile, BpSR11, showed a decreasing trend from 25% to 30% in 1998 to 2005 to 13% in 2007 to 2009, and there were increases in BpSR3 and BpSR10 from 0% and 8% to 21% and 22%, respectively. One difference between these profiles is that BpSR11 contains isolates harboring the fim3-2 allele and BpSR3 and BpSR10 contain isolates harboring the fim3-1 allele. The total proportion of the five predominant profiles increased from 44% in 1998 to 2001 to 63% in 2004 to 2005 to 70% in 2007 to 2009. In conclusion, common PFGE profiles were identified in B. pertussis populations circulating in European countries with different vaccination programs and different vaccine coverages. These prevalent isolates contain the novel pertussis toxin promoter ptxP3 allele. However, there is evidence for diversifying selection between ptxP3 strains characterized by distinct PFGE profiles. This work shows that, even within a relatively short time span of 10 years, successful isolates which spread through Europe and cause large shifts in B. pertussis populations may emerge.
authors.affiliation: Swedish Institute for Communicable Disease Control, Solna, Sweden.
authors.forename: Abdolreza
authors.initials: A
authors.lastname: Advani
authors.forename: Hans O
authors.initials: HO
authors.lastname: Hallander
authors.forename: Tine
authors.initials: T
authors.lastname: Dalby
authors.forename: Karen Angeliki
authors.initials: KA
authors.lastname: Krogfelt
authors.forename: Nicole
authors.initials: N
authors.lastname: Guiso
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Njamkepo
authors.forename: Carl Heinz Wirsing
authors.initials: CH
authors.lastname: von Könnig
authors.forename: Marion
authors.initials: M
authors.lastname: Riffelmann
authors.forename: Frits R
authors.initials: FR
authors.lastname: Mooi
authors.forename: Per
authors.initials: P
authors.lastname: Sandven
authors.forename: Anna
authors.initials: A
authors.lastname: Lutynska
authors.forename: Norman K
authors.initials: NK
authors.lastname: Fry
authors.forename: Jussi
authors.initials: J
authors.lastname: Mertsola
authors.forename: Qiushui
authors.initials: Q
authors.lastname: He
mesh_terms: D001886:Bordetella pertussis / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification; D002675:Child, Preschool; D016000:Cluster Analysis; D016521:Electrophoresis, Gel, Pulsed-Field; D005060:Europe / Q000453:epidemiology; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010567:Pertussis Vaccine / Q000276:immunology; D010802:Phylogeny; D014917:Whooping Cough / Q000453:epidemiology / Q000266:history / Q000382:microbiology* / Q000517:prevention & control
chemical_list: D010567:Pertussis Vaccine